V. Richter: "The low toxicity and originality of the pharmaceutical agent are its major advantages"

Abstract

There is no question that the government needs to provide vigorous financial support to Russian researchers looking to design new drugs. A different question is to what extent should the government participate in the financing and at
what point should industrial investors join in?